Shandong Xinhua Pharmaceutical (00719) has released its results for the nine months ended September 30, 2026.
Operating revenue came in at 6.061 billion yuan (RMB, same below), a decrease of 10.38% year-on-year.
Net profit attributable to shareholders of the listed company was 195 million yuan, down 23.88% year-on-year.
Basic earnings per share stood at 0.28 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments